CIK 0001937653
- Non-accelerated filer
- Smaller reporting company
Zymeworks Inc.
Sign in to watch- Ticker
- ZYME
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 883099146
- Phone
- +1 302-274-8744
- Business address
- 108 PATRIOT DRIVE, SUITE A, MIDDLETOWN, DE, 19709
- Former names
- Zymeworks Delaware Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,393,518
- in 2 filings
Net −$1,393,518. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-11-13 | Moore Paul Andrew Chief Scientific Officer | Option exercise | +25,000 | $5.82 | $146K | 73,497 |
| 2026-11-13 | Moore Paul Andrew Chief Scientific Officer | Sale | −7,367 | $26.14 | $193K | 66,130 |
| 2026-11-13 | Moore Paul Andrew Chief Scientific Officer | Sale | −7,374 | $26.09 | $192K | 58,756 |
| 2026-11-13 | Moore Paul Andrew Chief Scientific Officer | Sale | −25,000 | $26.04 | $651K | 33,756 |
| 2026-11-13 | Moore Paul Andrew Chief Scientific Officer | Option exercise · Stock Option (Right to Buy) | −25,000 | 175,000 | ||
| 2026-10-09 | Schayowitz Adam EVP, Head of R&D | Option exercise | +37,037 | 37,037 | ||
| 2026-10-09 | Schayowitz Adam EVP, Head of R&D | Sale | −13,832 | $25.85 | $358K | 23,205 |
| 2026-10-09 | Schayowitz Adam EVP, Head of R&D | Option exercise · Restricted Stock Unit | −37,037 | 74,074 | ||
| 2026-07-06 | Hollywood Mark EVP & Chief Operating Officer | Grant or award | +939 | $22.22 | $21K | 133,852 |
| 2026-05-13 | Schneider Paul R EVP, General Counsel | Grant or award · Stock Option (Right to Buy) | +178,000 | 178,000 | ||
| 2026-05-13 | Schneider Paul R EVP, General Counsel | Grant or award · Restricted Stock Unit | +119,000 | 119,000 | ||
| 2026-04-09 | Schayowitz Adam See Remarks | Grant or award · Stock Option (Right to Buy) | +70,000 | 70,000 | ||
| 2026-04-09 | Schayowitz Adam See Remarks | Grant or award · Restricted Stock Unit | +47,000 | 47,000 | ||
| 2026-04-09 | Schayowitz Adam See Remarks | Grant or award · Performance Stock Unit | +76,000 | 76,000 | ||
| 2026-04-09 | Platshon Scott EVP, Chief Business Officer | Grant or award · Stock Option (Right to Buy) | +70,000 | 70,000 | ||
| 2026-04-09 | Platshon Scott EVP, Chief Business Officer | Grant or award · Restricted Stock Unit | +47,000 | 47,000 | ||
| 2026-04-09 | Platshon Scott EVP, Chief Business Officer | Grant or award · Performance Stock Unit | +76,000 | 76,000 | ||
| 2026-04-06 | Stafford Kristin EVP, Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +178,000 | 178,000 | ||
| 2026-04-06 | Stafford Kristin EVP, Chief Financial Officer | Grant or award · Restricted Stock Unit | +119,000 | 119,000 | ||
| 2026-04-06 | Stafford Kristin EVP, Chief Financial Officer | Grant or award · Restricted Stock Unit | +50,000 | 50,000 |
Page 1 of 12 · 229 trades